APA (7th ed.) Citation

Ngaimisi, E., & Burhenne, J. (2014). Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. The journal of antimicrobial chemotherapy, 69(12), . https://doi.org/10.1093/jac/dku286

Chicago Style (17th ed.) Citation

Ngaimisi, Eliford, and Jürgen Burhenne. "Pharmacokinetic and Pharmacogenomic Modelling of the CYP3A Activity Marker 4β-hydroxycholesterol During Efavirenz Treatment and Efavirenz/rifampicin Co-treatment." The Journal of Antimicrobial Chemotherapy 69, no. 12 (2014). https://doi.org/10.1093/jac/dku286.

MLA (9th ed.) Citation

Ngaimisi, Eliford, and Jürgen Burhenne. "Pharmacokinetic and Pharmacogenomic Modelling of the CYP3A Activity Marker 4β-hydroxycholesterol During Efavirenz Treatment and Efavirenz/rifampicin Co-treatment." The Journal of Antimicrobial Chemotherapy, vol. 69, no. 12, 2014, https://doi.org/10.1093/jac/dku286.